• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Software firm allies with Amersham

Article

Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView

Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView multimodality workstation to provide quantitative and reproducible methods of image analysis. Molecular imaging promises exact and sensitive information, leading to earlier and more accurate diagnoses-but only if the data can be quantified, according to the two companies. Although Mirada has established relationships with hardware manufacturers, this is its first with a company engaged primarily in pharmaceuticals.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.